Ovid Therapeutics Inc.
NASDAQ:OVIDBiotechnology
-$0.11 today
- Market cap
- $426.53M
- Beta
- 0.18
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.33
Volume 2.16M
Average 3.07M
OVID Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Ovid Therapeutics Inc.NASDAQ: OVID
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation outflow shrinks to $0
Q1 FY2026 stock-based compensation was $0, compared with $1.28M a year earlier. Trailing-twelve-month stock-based compensation was $2.41M. Over 3 fiscal years it compounded at -9.8% a year.
Context
- Stock-based compensation amounted to 66.3% of revenue in FY2025, down 1042.5 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $603.5K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 4.81M USD
- Year-over-year change
- -23.4%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.81M | -23.4% |
| FY2024 | 2024-12-31 | 6.28M | -13.9% |
| FY2023 | 2023-12-31 | 7.29M | +11.1% |
| FY2022 | 2022-12-31 | 6.56M | — |
| FY2021 | 2021-12-31 | 0 | — |
Stock-Based Compensation vs competitors
How OVID compares with its peers on the latest reported figures
- OVID's LTM Mar 2026 stock-based compensation of $2.41M is the smallest of the 11 companies compared; the peer median is $19.95M.
- Its year-over-year change of -6.9% is the 5th highest of 11, against a peer median of -9.0%.
- Stock-based compensation amounts to 33.9% of revenue for OVID, versus a peer median of 57.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $142.83M | -11.3% | +5.5% | 21.3% | |
| LTM Mar 2026 | $47.93M | +107.3% | -8.3% | 60.1% | |
| LTM Mar 2026 | $35.22M | -20.0% | +6.1% | — | |
| LTM Mar 2026 | $26.2M | -9.4% | +12.2% | 81.7% | |
| LTM Mar 2026 | $21.73M | +42.8% | — | 30.3% | |
| LTM Jun 2026 | $18.17M | +39.2% | -9.7% | 331.3% | |
| LTM Mar 2026 | $13.6M | -8.6% | +16.5% | 37.3% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $11.19M | -19.1% | +89.6% | — |
| LTM Mar 2026 | $8.33M | +7.1% | +52.3% | 57.3% | |
| LTM Mar 2026 | $3.41M | -69.9% | +124.6% | — | |
| LTM Mar 2026 | $2.41M | -6.9% | -9.8% | 33.9% | |
| Peer median (excluding OVID) | $19.95M | -9.0% | +12.2% | 57.3% | |
Competitors are the stored peer set for OVID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 119.84M | (54.17M) | (52.34M) | (26.43M) | (17.41M) |
| Depreciation & Amortization | 237K | 1.38M | 1.6M | 613K | 273K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 6.56M | 7.29M | 6.28M | 4.81M |
| Change in Working Capital | (16.81M) | (8.23M) | 2.39M | (150K) | (4.1M) |
| Accounts Receivables | 141.76K | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.7M | (5.17M) | 1.75M | (512K) | (1.23M) |
| Other Working Capital | (18.66M) | (3.06M) | 635.51K | 362K | (2.87M) |
| Other Non-Cash Items | 15.35M | (764.94K) | (4.71M) | (36.26M) | (21.9M) |
| Operating Cash Flow | 118.61M | (55.23M) | (45.78M) | (55.96M) | (38.33M) |
| Capital Expenditures | (189.41K) | (1.42M) | (137.46K) | (71K) | 0 |
| Acquisitions (Net) | (1.63M) | (2.5M) | (10M) | 0 | 0 |
| Purchases of Investments | (1.63M) | (172.96M) | (112.44M) | (73.25M) | (91.85M) |
| Sales of Investments | 0 | 90M | 120M | 128M | 42M |
| Other Investing Activities | (5.4K) | (1M) | (97.15K) | (89K) | 0 |
| Investing Cash Flow | (1.82M) | (87.88M) | (2.58M) | 54.59M | (49.85M) |
| Debt Repayment | 0 | 0 | 30M | 0 | 0 |
| Common Stock Issued | 925.4K | 180.66K | 535.2K | 622K | 75.21M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (21.31K) | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 904.08K | 180.66K | 30.54M | 622K | 75.21M |
| Effect of Forex Changes | (1.93M) | 0 | 0 | 0 | (167K) |
| Net Change in Cash | 115.76M | (142.93M) | (17.83M) | (740K) | (13.15M) |
| Free Cash Flow | 118.42M | (56.65M) | (45.92M) | (56.03M) | (38.33M) |
Ovid Therapeutics Inc.
NASDAQ:OVID
Intrinsic Alpha fair value
Locked
Current Price
$2.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.